A multicenter prospective cohort assessed the efficacy of sunitinib, VEGFRs, KIT, PDGFRs, and tyrosine kinase inhibitor (TKI) in twenty-eight patients (nineteen male/nine female) with stage III and IV thymomas (8) and TC (20) who already received other systemic treatments [21]. This evidence concerns the gene KIT and thymoma.